Select Bibliography

Filter by any of these (after searching):

Lozanski, G.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.

Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - ASCO - J Clin Oncol - 2012

Abstract - Primary - Primary - Leukemia - CALGB-10502

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102)

Lozanski, G. , Sanford, B. , Mrozek, K. , Edwards, C. , Pearson, R. ... - ASH - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10102 , CALGB-8461 , CALGB-9665 , CALGB-9862

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - ASH - Blood - 2010

Abstract - Primary - Primary - Leukemia - CALGB-10002

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

Stock, W. , Sanford, B. , Lozanski, G. , Vij, R. , Byrd, J. C. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-10102